89 related articles for article (PubMed ID: 11759148)
1. [New molecules].
Sternon J
J Pharm Belg; 2001; 56(5):105-10. PubMed ID: 11759148
[TBL] [Abstract][Full Text] [Related]
2. [New drugs].
Sternon J
Rev Med Brux; 2001 Sep; 22(4):A394-400. PubMed ID: 11680207
[TBL] [Abstract][Full Text] [Related]
3. Comparison of repaglinide and nateglinide in combination with metformin: response to Raskin et al.
Baron MA
Diabetes Care; 2003 Dec; 26(12):3361-2; author reply 3362-3. PubMed ID: 14633839
[No Abstract] [Full Text] [Related]
4. [symbol: see text] Nateglinide and [symbol: see text] repaglinide for type 2 diabetes?
Drug Ther Bull; 2003 Jul; 41(7):52-4. PubMed ID: 12879789
[TBL] [Abstract][Full Text] [Related]
5. Postprandial hyperglycemia: are all sulfonylureas created equal?
Kapoor JR
Am J Cardiol; 2008 Feb; 101(4):554-5. PubMed ID: 18312779
[No Abstract] [Full Text] [Related]
6. Drugs for type 2 diabetes.
Treat Guidel Med Lett; 2008 Jul; 6(71):47-54. PubMed ID: 18583949
[No Abstract] [Full Text] [Related]
7. [Antidiabetic Drugs and the Kidney].
Candido R
G Ital Nefrol; 2016 Malattie Metaboliche e Rene; 33(S68):. PubMed ID: 27960013
[No Abstract] [Full Text] [Related]
8. Preventing the progressive nature of type 2 diabetes.
Cardiovasc J S Afr; 2002; 13(4):211-3. PubMed ID: 12402899
[No Abstract] [Full Text] [Related]
9. [Insulin analogs and new oral antidiabetic drugs].
Koivisto V
Duodecim; 1999; 115(20):2197-202. PubMed ID: 11973922
[No Abstract] [Full Text] [Related]
10. Diabetes under control: Understanding oral antidiabetic agents.
Longo R
Am J Nurs; 2010 Feb; 110(2):49-52. PubMed ID: 20107402
[No Abstract] [Full Text] [Related]
11. Hypersensitivity to repaglinide.
Rojas P; Sánchez L; Santos A; Góõmez MP; Blanco H; Laguna JJ
J Investig Allergol Clin Immunol; 2011; 21(3):245-7. PubMed ID: 21548456
[TBL] [Abstract][Full Text] [Related]
12. Glimepiride and serum adiponectin level in type 2 diabetic subjects: response to Nagasaka et al.
Yoshioka K; Yoshida T; Yoshikawa T
Diabetes Care; 2003 Dec; 26(12):3360-1; author reply 3361. PubMed ID: 14633838
[No Abstract] [Full Text] [Related]
13. Meglitinide analogues in the treatment of type 2 diabetes mellitus.
Landgraf R
Drugs Aging; 2000 Nov; 17(5):411-25. PubMed ID: 11190420
[TBL] [Abstract][Full Text] [Related]
14. [New glucose regulator. More comfort for the type 2 diabetic patient].
MMW Fortschr Med; 2001 Feb; 143(6):57. PubMed ID: 11247371
[No Abstract] [Full Text] [Related]
15. [Sulfonylureas and glinides].
Hirose T
Nihon Rinsho; 2006 Dec; 64 Suppl 9():646-53. PubMed ID: 17458297
[No Abstract] [Full Text] [Related]
16. [Sulfonylureas and glinides].
Kudo K; Hirose T
Nihon Rinsho; 2011 Jan; 69 Suppl 1():645-53. PubMed ID: 21766676
[No Abstract] [Full Text] [Related]
17. Senaglinide. A 4166, AY 4166, Fastic, SDZ DJN 608, Starlix, Starsis, YM 026, Nateglinide.
Drugs R D; 1999 Aug; 2(2):123-6. PubMed ID: 10820657
[No Abstract] [Full Text] [Related]
18. [Fasting hyperglycemia and postprandial glucose peaks. Diabetes therapy mustact on 2 sides].
MMW Fortschr Med; 2003 Aug; 145(33-34):59. PubMed ID: 14526583
[No Abstract] [Full Text] [Related]
19. Should diabetic patients treated long-term with sulfonylureas be switched to nateglinide?
Sevinc A
Arch Intern Med; 2003 Jul; 163(14):1741. PubMed ID: 12885691
[No Abstract] [Full Text] [Related]
20. Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.
Ferrannini E; DeFronzo RA
Eur Heart J; 2015 Sep; 36(34):2288-96. PubMed ID: 26063450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]